PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 135 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,000 | +50.0% | 0 | -100.0% | 0.00% | – |
| Q2 2022 | $2,000 | -71.4% | 307 | 0.0% | 0.00% | – |
| Q1 2022 | $7,000 | -30.0% | 307 | 0.0% | 0.00% | – |
| Q4 2021 | $10,000 | +100.0% | 307 | 0.0% | 0.00% | – |
| Q3 2021 | $5,000 | -64.3% | 307 | 0.0% | 0.00% | – |
| Q2 2021 | $14,000 | -68.9% | 307 | -82.3% | 0.00% | – |
| Q1 2021 | $45,000 | +200.0% | 1,739 | -23.8% | 0.00% | – |
| Q4 2018 | $15,000 | -77.3% | 2,282 | -64.5% | 0.00% | – |
| Q3 2018 | $66,000 | -25.0% | 6,426 | -51.0% | 0.00% | – |
| Q2 2018 | $88,000 | +87.2% | 13,126 | +141.9% | 0.00% | – |
| Q1 2018 | $47,000 | – | 5,426 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |